Compare AbCellera Biologics Inc (ABCL) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Verisign, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Verisign, Inc. trades at $269.23 (market cap $24.28B). The key difference: Verisign, Inc. is far larger — about 10.3× AbCellera Biologics Inc's market cap, and Verisign, Inc. pays a 1.21% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | VRSN | |
|---|---|---|
Market Cap | $2.35B | $24.28B |
Sector | Health | Technology |
52-Week High | $8.12 | $310.00 |
52-Week Low | $2.78 | $211.49 |
Enterprise Value | $1.99B | $25.52B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VeriSign (VRSN) trades at $266.78, up 4.04% on the day, with a bearish technical signal and mixed earnings history including a Q1 2026 beat. The stock shows strong fundamentals with 49.96% net income margin and $825.7M net income for 2025, though negative shareholder equity remains a concern. Recent news highlights AI-driven domain growth and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic with 57% analyst buy ratings and a $327.67 consensus target offering 23% upside. Key risks include contract renewals, AI disruption potential, and high debt levels. Revenue growth stability and margin strength support investment case, but technical resistance near $266 requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
